Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific databaseMaurizio Genuardi, Michael Farrell, Susan M. Farrington et al.|Nature Genetics|2013Cited by 476
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal CancerJun Watanabe, Takayuki Yoshino, Kei Muro et al.|JAMA|2023Cited by 255
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal CancerNaohiro Tomita, Hideyuki Ishida, Kohji Tanakaya et al.|International Journal of Clinical Oncology|2021Cited by 157
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerKohei Shitara, Takayuki Yoshino, Kei Muro et al.|Nature Medicine|2024Cited by 108
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.Takayuki Yoshino, Kei Muro, Jun Watanabe et al.|Journal of Clinical Oncology|2022Cited by 69